Orgenesis Inc. (ORGS): Price and Financial Metrics

Orgenesis Inc. (ORGS)

Today's Latest Price: $4.95 USD

0.09 (1.85%)

Updated Nov 27 1:00pm

Add ORGS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ORGS Stock Summary

  • ORGS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.52 -- higher than only 6.33% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of -41.92%, Orgenesis Inc's debt growth rate surpasses only 7.43% of about US stocks.
  • As for revenue growth, note that ORGS's revenue has grown -48.14% over the past 12 months; that beats the revenue growth of merely 5.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Orgenesis Inc are AMBA, CVM, WATT, IPHI, and CUE.
  • ORGS's SEC filings can be seen here. And to visit Orgenesis Inc's official web site, go to

ORGS Stock Price Chart Interactive Chart >

Price chart for ORGS

ORGS Price/Volume Stats

Current price $4.95 52-week high $8.20
Prev. close $4.86 52-week low $2.35
Day low $4.88 Volume 13,000
Day high $4.99 Avg. volume 83,883
50-day MA $4.93 Dividend yield N/A
200-day MA $5.26 Market Cap 119.57M

Orgenesis Inc. (ORGS) Company Bio

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. The company was founded in 2008 and is based in Germantown, Maryland.

ORGS Latest News Stream

Event/Time News Detail
Loading, please wait...

ORGS Latest Social Stream

Loading social stream, please wait...

View Full ORGS Social Stream

Latest ORGS News From Around the Web

Below are the latest news stories about Orgenesis Inc that investors may wish to consider to help them evaluate ORGS as an investment opportunity.

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

Provides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020 GERMANTOWN, Md., Aug. 07, 2020 …

Benzinga | August 7, 2020

Orgenesis partners with Educell to conduct cell-based research programs

Orgenesis (ORGS) has collaborated with Educell Ltd., a European cell therapy company.Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers. The first collaboration will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in...

Seeking Alpha | July 14, 2020

5 Health Care Stocks Trading With Low Price-Earnings Ratios

Genesis tops the list Continue reading...

Yahoo | July 14, 2020

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company. Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.The companies will leverage the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform which includes point of care (POCare) Networks, POCare Therapeutics and a POCare Technologies suite of proprietary and in-licensed technologies that have been engineered to create custom...

Yahoo | July 14, 2020

Orgenesis Added to Russell 3000® Index

Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

Yahoo | June 29, 2020

Read More 'ORGS' Stories Here

ORGS Price Returns

1-mo 6.22%
3-mo -5.53%
6-mo -31.82%
1-year 59.68%
3-year 10.00%
5-year 25.00%
YTD 6.22%
2019 -0.43%
2018 -18.68%
2017 54.65%
2016 -3.09%
2015 -44.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8657 seconds.